Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Sets Up New Office to Take Reports on Inappropriate Detailing Activities from Healthcare Providers
The Ministry of Health, Labor and Welfare (MHLW) set up an office to take reports from healthcare professionals on the inappropriate detailing activities of sales reps on October 1. The new office takes reports on questionable detailing activities from all…
To read the full story
Related Article
- MHLW Finds 57 Suspected Violations in Drug Detailing Activities in FY2019
July 30, 2020
- MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
January 6, 2020
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- MHLW Planning to Launch Report System on Inappropriate Detailing Activity as Early as Summer
May 21, 2019
- 74 Suspected Violations Found in Sales Reps’ Advertising Activities: MHLW
May 21, 2019
REGULATORY
- Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…